Ponikowska Małgorzata, Vellone Ercole, Czapla Michał, Uchmanowicz Izabella
Division of Clinical Trials and Registries, University Centre of General Dermatology and Oncodermatology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland.
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Psoriasis (Auckl). 2025 May 1;15:175-183. doi: 10.2147/PTT.S519420. eCollection 2025.
Psoriasis, a chronic inflammatory disease affecting approximately 3% of the global population, presents complex challenges that extend beyond its physical manifestations. This comprehensive review examines the multidimensional impact of psoriasis on patients' lives, encompassing physical, psychological, and social aspects. We analyze current therapeutic approaches, from traditional systemic treatments to cutting-edge biological therapies and emerging oral medications, evaluating their efficacy, limitations, and accessibility. The review explores how disease severity correlates with quality of life measures and psychological burden, noting the high prevalence of depression (20%), anxiety (21%), and suicidal ideation (0.77%) among affected individuals. However, emerging evidence suggests that clinical severity, as measured by PASI or BSA, does not always correlate with the psychoemotional burden experienced by patients, highlighting the need for a more comprehensive assessment of disease impact. We discuss the evolution of treatment strategies, highlighting recent developments in targeted therapies, including JAK inhibitors, particularly selective TYK2 inhibitors, and PDE4 inhibitors, which offer promising alternatives to traditional treatments. Additionally, we examine the role of various assessment tools and quality of life measures in evaluating treatment outcomes. The analysis emphasizes the need for a holistic approach to patient care that integrates medical interventions with psychological support, addressing both the visible and invisible burdens of the disease. This review underscores the importance of personalized treatment strategies that consider not only clinical efficacy but also patient preferences, accessibility, and long-term safety profiles.
银屑病是一种慢性炎症性疾病，影响着全球约3%的人口，它带来的复杂挑战远远超出其身体表现。这篇综述全面审视了银屑病对患者生活的多维度影响，涵盖身体、心理和社会方面。我们分析了当前的治疗方法，从传统的全身治疗到前沿的生物疗法以及新兴的口服药物，评估它们的疗效、局限性和可及性。该综述探讨了疾病严重程度与生活质量指标及心理负担之间的关联，指出在受影响个体中抑郁症（20%）、焦虑症（21%）和自杀意念（0.77%）的高患病率。然而，新出现的证据表明，以银屑病面积和严重程度指数（PASI）或体表面积（BSA）衡量的临床严重程度并不总是与患者所经历的心理情绪负担相关，这凸显了对疾病影响进行更全面评估的必要性。我们讨论了治疗策略的演变，强调了靶向治疗的最新进展，包括Janus激酶（JAK）抑制剂，特别是选择性酪氨酸激酶2（TYK2）抑制剂和磷酸二酯酶4（PDE4）抑制剂，它们为传统治疗提供了有前景的替代方案。此外，我们研究了各种评估工具和生活质量指标在评估治疗结果中的作用。分析强调了采取整体方法进行患者护理的必要性，这种方法将医疗干预与心理支持相结合，解决疾病的可见和无形负担。这篇综述强调了个性化治疗策略的重要性，该策略不仅要考虑临床疗效，还要考虑患者偏好、可及性和长期安全性。
